Nicotine patch and lozenges for Tobacco Use

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Tobacco Use+3 More
Nicotine patch and lozenges - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new smoking cessation and relapse prevention intervention for people with lung cancer.

Eligible Conditions
  • Tobacco Use
  • Lung Cancers
  • Smoking

Treatment Effectiveness

Study Objectives

8 Primary · 0 Secondary · Reporting Duration: at 3 months

Baseline
Percentage of Participants who meet inclusion criteria
Percentage of participants completing baseline assessment
Percentage of participants who agree to participate in the study
at 3 months
Percentage of participants completing the 3 month follow-up assessments
at 6 months
Completion rate of MAPS calls for UC+MAPS+RP participants - Demand
Percentage of UC+MAPS+RP participants who viewed the web-based video -Demand
Percentage of participants completing the 6 month follow-up assessments
Treatment satisfaction - Acceptability

Trial Safety

Trial Design

2 Treatment Groups

Group 1: Usual Care
1 of 2
Group 2: Usual Care + Motivation and Problem Solving + Relapse Prevention
1 of 2
Active Control
Experimental Treatment

30 Total Participants · 2 Treatment Groups

Primary Treatment: Nicotine patch and lozenges · No Placebo Group · N/A

Group 2: Usual Care + Motivation and Problem Solving + Relapse PreventionExperimental Group · 4 Interventions: Florida Tobacco Quitline, Access to a web-based video, Telephone counseling sessions, Nicotine patch and lozenges · Intervention Types: Behavioral, Behavioral, Behavioral, Drug
Group 1: Usual CareActiveComparator Group · 2 Interventions: Florida Tobacco Quitline, Nicotine patch and lozenges · Intervention Types: Behavioral, Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at 3 months

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
489 Previous Clinical Trials
123,322 Total Patients Enrolled
2 Trials studying Tobacco Use
306 Patients Enrolled for Tobacco Use
Vani N Simmons, PhDPrincipal InvestigatorMoffitt Cancer Center
Jennifer I Vidrine, PhDPrincipal InvestigatorMoffitt Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a diagnosis of lung cancer.
You must be able to read and write English.
You must have a valid home address.\n

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: October 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.